Terminated PHASE1 INTERVENTIONAL 4-arm NCT01200004

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

A Phase I Study of Epigenetic Immunomodulation Through the Use of Azacitidine, Lenalidomide, and Grifola Frondosa in Patients With Advanced Malignancy

Sponsor: M.D. Anderson Cancer Center

Conditions Advanced Cancers

Interventions Azacitidine Grifola Frondosa Lenalidomide

Updated 6 times since 2017 Last updated: Jul 31, 2013 Started: Apr 30, 2012 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow Accrual.

Other terminated trials from M.D. Anderson Cancer Center

See all terminations from M.D. Anderson Cancer Center

Other Advanced Cancers trials with similar outcome

Browse all Advanced Cancers trials

A PHASE1 clinical study on Advanced Cancers, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 6 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Yukiguni Maitake Company Ltd.

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States